NCT00571142终止3 期
Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)
Asociación para Evitar la Ceguera en México2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2007年11月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Retinal thickness
研究概览
简要总结
To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Older than 25 yo
- •Diffuse diabetic macular edema with or without previous treatment
排除标准
- •Another retinal disease
- •Pregnancy
研究组 & 干预措施
2
Active Comparator
Without renal disease
干预措施: Bevacizumab + pars plana vitrectomy (Procedure)
1
Active Comparator
Renal disease
干预措施: Bevacizumab + Pars plana vitrectomy (Procedure)
结局指标
主要结局
Retinal thickness
时间窗: 3 months
次要结局
- Visual acuity(3 months)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous HemorrhageVitreous Hemorrhage Secondary to PDRNCT01091896University of Sao Paulo1
已完成
1 期
Intravitreal Bevacizumab and Low Fluence Photodynamic TherapyMyopiaNCT00802126University of Campania "Luigi Vanvitelli"16
Unknown
2 期
Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMDMacular DegenerationNCT00684853Federal University of São Paulo50
已完成
2 期
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)Age Related Macular DegenerationMacular EdemaChoroidal NeovascularizationNCT00729846California Retina Consultants22
Unknown
3 期
Bevacizumab Versus Ranibizumab in Age Related Macular DegenerationAge Related Macular DegenerationNCT01014468Instituto de Olhos de Goiania500